Publications by Christopher Alviedo

Publications by authors named "Christopher Alviedo"

Page 1 of 1

Treatment of a clinically determined lower-risk stage III non-lymphoblastic Non-Hodgkin lymphoma with less intensive therapy does not impact negatively on outcome.

Asim F Belgaumi Lobna Shalaby Amani Al-Kofide M Ashraf Chaudhary Christopher Alviedo

Pediatr Blood Cancer

March 2006

Stage III NHL was divided into lower-risk (LR) or high-risk (HR) groups. Results of treatment were retrospectively reviewed for patients between 1993 through 2000. An intensive multiagent protocol was used for IIIHR, and a CHOP-based, milder treatment for IIILR.

View Article and Find Full Text PDF

- Christopher Alviedo's research primarily focuses on pediatric oncology, specifically the treatment of Non-Hodgkin lymphoma (NHL) in children, with an emphasis on stratifying risk levels and optimizing therapy.
- His 2006 study evaluated the effectiveness of less intensive therapies on lower-risk stage III non-lymphoblastic NHL, finding that these approaches do not adversely affect patient outcomes when compared to more aggressive treatments.
- Alviedo's work contributes to the increasing trend in tailoring cancer treatment to reduce toxicity and improve quality of life for pediatric patients while still maintaining successful survival rates.

Publications by authors named "Christopher Alviedo"

Treatment of a clinically determined lower-risk stage III non-lymphoblastic Non-Hodgkin lymphoma with less intensive therapy does not impact negatively on outcome.

Synopsis of recent research by authors named "Christopher Alviedo"